Table of contents
Acute myeloid leukemia
What's new
Updated 2024 ASTCT guidelines for the evaluation and management of donor-specific anti-HLA antibodies in patients undergoing allogeneic hematopoietic stem cell transplantation .
Background
Overview
Guidelines
Key sources
Classification and risk stratification
Diagnostic procedures
More topics in this section
Ancillary testing
Medical management
More topics in this section
Induction chemotherapy (patients ineligible for standard treatment)
Consolidation therapy
Management of relapsed/refractory disease
Management of thrombocytopenia
Management of DIC
Management of donor-specific anti-HLA antibodies (prevention)
Management of donor-specific anti-HLA antibodies (testing)
Management of donor-specific anti-HLA antibodies (desensitization therapy)
Management of donor-specific anti-HLA antibodies (follow-up)
Management of non-donor-specific anti-HLA antibodies
Therapeutic procedures
More topics in this section
Blood transfusion
Specific circumstances
More topics in this section
Pregnant patients (general principles of management)
Pregnant patients (chemotherapy)
Pregnant patients (supportive therapy)
Pregnant patients (delivery)
Patients with APL (induction and consolidation therapy)
Patients with clonal eosinophilia
Patients with CNS involvement
Preventative measures
More topics in this section
Antifungal prophylaxis